354 related articles for article (PubMed ID: 21556485)
1. Translational research and therapeutic perspectives in dysferlinopathies.
Barthélémy F; Wein N; Krahn M; Lévy N; Bartoli M
Mol Med; 2011; 17(9-10):875-82. PubMed ID: 21556485
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic exon skipping for dysferlinopathies?
Aartsma-Rus A; Singh KH; Fokkema IF; Ginjaar IB; van Ommen GJ; den Dunnen JT; van der Maarel SM
Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676
[TBL] [Abstract][Full Text] [Related]
3. The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments.
Anwar S; Yokota T
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540676
[TBL] [Abstract][Full Text] [Related]
4. Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.
Poudel BH; Fletcher S; Wilton SD; Aung-Htut M
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891760
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.
Nguyen K; Bassez G; Krahn M; Bernard R; Laforêt P; Labelle V; Urtizberea JA; Figarella-Branger D; Romero N; Attarian S; Leturcq F; Pouget J; Lévy N; Eymard B
Arch Neurol; 2007 Aug; 64(8):1176-82. PubMed ID: 17698709
[TBL] [Abstract][Full Text] [Related]
6. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy.
Illarioshkin SN; Ivanova-Smolenskaya IA; Greenberg CR; Nylen E; Sukhorukov VS; Poleshchuk VV; Markova ED; Wrogemann K
Neurology; 2000 Dec; 55(12):1931-3. PubMed ID: 11134403
[TBL] [Abstract][Full Text] [Related]
7. Dysferlinopathies: Clinical and genetic variability.
Ivanova A; Smirnikhina S; Lavrov A
Clin Genet; 2022 Dec; 102(6):465-473. PubMed ID: 36029111
[TBL] [Abstract][Full Text] [Related]
8. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
[TBL] [Abstract][Full Text] [Related]
9. Dysferlin protein analysis in limb-girdle muscular dystrophies.
Vainzof M; Anderson LV; McNally EM; Davis DB; Faulkner G; Valle G; Moreira ES; Pavanello RC; Passos-Bueno MR; Zatz M
J Mol Neurosci; 2001 Aug; 17(1):71-80. PubMed ID: 11665864
[TBL] [Abstract][Full Text] [Related]
10. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.
Nguyen K; Bassez G; Bernard R; Krahn M; Labelle V; Figarella-Branger D; Pouget J; Hammouda el H; Béroud C; Urtizberea A; Eymard B; Leturcq F; Lévy N
Hum Mutat; 2005 Aug; 26(2):165. PubMed ID: 16010686
[TBL] [Abstract][Full Text] [Related]
11. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s).
Weiler T; Bashir R; Anderson LV; Davison K; Moss JA; Britton S; Nylen E; Keers S; Vafiadaki E; Greenberg CR; Bushby CR; Wrogemann K
Hum Mol Genet; 1999 May; 8(5):871-7. PubMed ID: 10196377
[TBL] [Abstract][Full Text] [Related]
12. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies).
Anderson LV; Harrison RM; Pogue R; Vafiadaki E; Pollitt C; Davison K; Moss JA; Keers S; Pyle A; Shaw PJ; Mahjneh I; Argov Z; Greenberg CR; Wrogemann K; Bertorini T; Goebel HH; Beckmann JS; Bashir R; Bushby KM
Neuromuscul Disord; 2000 Dec; 10(8):553-9. PubMed ID: 11053681
[TBL] [Abstract][Full Text] [Related]
13. Dysferlinopathy: a clinical and histopathological study of 28 patients from India.
Nalini A; Gayathri N
Neurol India; 2008; 56(3):379-85; discussion 386-7. PubMed ID: 18974568
[TBL] [Abstract][Full Text] [Related]
14. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B - the usefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies.
Szymanska S; Rokicki D; Karkucinska-Wieckowska A; Szymanska-Debinska T; Ciara E; Ploski R; Grajkowska W; Pronicki M
Folia Neuropathol; 2014; 52(4):452-6. PubMed ID: 25574751
[TBL] [Abstract][Full Text] [Related]
15. Dysferlin mutation analysis in a group of Italian patients with limb-girdle muscular dystrophy and Miyoshi myopathy.
Kawabe K; Goto K; Nishino I; Angelini C; Hayashi YK
Eur J Neurol; 2004 Oct; 11(10):657-61. PubMed ID: 15469449
[TBL] [Abstract][Full Text] [Related]
16. Morpholino-Mediated Exons 28-29 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay.
Anwar S; Yokota T
Methods Mol Biol; 2023; 2587():183-196. PubMed ID: 36401031
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy.
Lostal W; Bartoli M; Roudaut C; Bourg N; Krahn M; Pryadkina M; Borel P; Suel L; Roche JA; Stockholm D; Bloch RJ; Levy N; Bashir R; Richard I
PLoS One; 2012; 7(5):e38036. PubMed ID: 22666441
[TBL] [Abstract][Full Text] [Related]
18. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies.
Bolduc V; Marlow G; Boycott KM; Saleki K; Inoue H; Kroon J; Itakura M; Robitaille Y; Parent L; Baas F; Mizuta K; Kamata N; Richard I; Linssen WH; Mahjneh I; de Visser M; Bashir R; Brais B
Am J Hum Genet; 2010 Feb; 86(2):213-21. PubMed ID: 20096397
[TBL] [Abstract][Full Text] [Related]
19. [Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)].
Aoki M; Takahashi T
Rinsho Shinkeigaku; 2005 Nov; 45(11):938-42. PubMed ID: 16447768
[TBL] [Abstract][Full Text] [Related]
20. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
Azakir BA; Di Fulvio S; Kinter J; Sinnreich M
J Biol Chem; 2012 Mar; 287(13):10344-10354. PubMed ID: 22318734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
